Aeolus Pharmaceuticl Stock Working Capital
| AOLS Stock | USD 0.0001 0.00 0.00% |
Aeolus Pharmaceuticl fundamentals help investors to digest information that contributes to Aeolus Pharmaceuticl's financial success or failures. It also enables traders to predict the movement of Aeolus Pink Sheet. The fundamental analysis module provides a way to measure Aeolus Pharmaceuticl's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeolus Pharmaceuticl pink sheet.
Aeolus |
Aeolus Pharmaceuticl Company Working Capital Analysis
Aeolus Pharmaceuticl's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Aeolus Pharmaceuticl Working Capital | 3.16 M |
Most of Aeolus Pharmaceuticl's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeolus Pharmaceuticl is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Aeolus Pharmaceuticl has a Working Capital of 3.16 M. This is 99.26% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 99.79% higher than that of the company.
Aeolus Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeolus Pharmaceuticl's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aeolus Pharmaceuticl could also be used in its relative valuation, which is a method of valuing Aeolus Pharmaceuticl by comparing valuation metrics of similar companies.Aeolus Pharmaceuticl is currently under evaluation in working capital category among its peers.
Aeolus Fundamentals
| Return On Equity | -1.86 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (5.31) % | |||
| Current Valuation | 167.29 K | |||
| Shares Outstanding | 152.09 M | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.22 X | |||
| Revenue | 2.08 M | |||
| Gross Profit | (805 K) | |||
| EBITDA | (3.85 M) | |||
| Net Income | (3.56 M) | |||
| Cash And Equivalents | 403 K | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (3.11 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 1.25 | |||
| Beta | -3.96 | |||
| Market Capitalization | 167.29 K | |||
| Total Asset | 4.17 M | |||
| Retained Earnings | (184.68 M) | |||
| Working Capital | 3.16 M | |||
| Current Asset | 4.13 M | |||
| Current Liabilities | 972 K | |||
| Z Score | -61.6 | |||
| Net Asset | 4.17 M |
About Aeolus Pharmaceuticl Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aeolus Pharmaceuticl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeolus Pharmaceuticl using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeolus Pharmaceuticl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aeolus Pink Sheet Analysis
When running Aeolus Pharmaceuticl's price analysis, check to measure Aeolus Pharmaceuticl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aeolus Pharmaceuticl is operating at the current time. Most of Aeolus Pharmaceuticl's value examination focuses on studying past and present price action to predict the probability of Aeolus Pharmaceuticl's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aeolus Pharmaceuticl's price. Additionally, you may evaluate how the addition of Aeolus Pharmaceuticl to your portfolios can decrease your overall portfolio volatility.